News Spectral Medical Inc.

Equities

EDT

CA8475771033

Pharmaceuticals

Delayed Toronto S.E. Other stock markets 08:08:24 16/03/2026 pm IST			5-day change	1st Jan Change
1.280 ^CAD	-0.78%		-1.54%	-11.11%

26/02	Spectral Medical Provides Update on PMA Submission	MT
26/02	Spectral Medical Inc. Provides Update on PMA Submission Timing for PMX-20R	CI

All News

26/02	Spectral Medical Provides Update on PMA Submission	MT
26/02	Spectral Medical Inc. Provides Update on PMA Submission Timing for PMX-20R	CI
26/02	Spectral Medical Provides Update on PMA Submission Timing for PMX-20R	AQ
10/12	Spectral Medical Inc. - Special Call
07/11	Spectral Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
07/11	Spectral Medical Provides Update on PMX Submission to FDA, Also Reports Q3 Loss	MT
07/11	Spectral Medical Brief: Says PMA Submission Targeted for Q1 2026 Following "Positive" Tigris results and ongoing FDA interactions	MT
07/11	Spectral Medical Brief: Total Q3 Revenue Increased to $675,000 compared to $502,000 for the same period in 2024	MT
07/11	Spectral Medical Q3 revenue up 34%	RE
07/11	Spectral Medical Announces Third Quarter 2025 Financial Results and Provides Corporate Update	AQ
29/25/29	Spectral Medical Inc. Files Base Shelf Prospectus and Revised AIF	AQ
16/25/16	Spectral Medical Provides Observational Study Update	MT
16/25/16	Spectral Medical Inc. Announces Publication of Eden Observational Study	CI
16/25/16	Spectral Medical Announces Publication of EDEN Observational Study	AQ
08/25/08	Spectral Medical Sponsors Unite for Sepsis Symposium, Chicago September 8 – 9, 2025	AQ
25/25/25	Spectral Medical Receives US$3 Million From Vantive	MT
25/25/25	Spectral Medical receives US$3 million from Vantive	RE
25/25/25	Spectral Medical Brief: Says Received US$3 Million From Vantive	MT
25/25/25	Spectral Medical Receives US$3 Million From Vantive	AQ
25/25/25	Spectral Medical Inc. announced that it has received $10 million in funding	CI
14/25/14	Spectral Medical Inc. - Special Call
13/25/13	Canadian Investment Regulatory Organization Trade Resumption - EDT	AQ
13/25/13	Spectral Medical and Vantive Release Topline Results From Phase 3 Endotoxic Septic Shock Study	MT
13/25/13	Canadian Investment Regulatory Organization Trading Halt - EDT	AQ
13/25/13	Spectral Medical and Vantive Announce Topline Results from Spectral’s Tigris Trial Evaluating PMX Hemoadsorption Therapy for Endotoxic Septic Shock	AQ